Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.

Growing evidence points to gallstones and cholecystitis as an underrecognized risk of GLP-1 RA therapy—pharmacists are well positioned to catch it early.

In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.

Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.

fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.

Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.

A former residency program director unpacks why this debate keeps resurfacing, and why some reasons people give for skipping residency may not hold up the way they think they do.

The FDA approval of pritelivir offers an oral treatment for refractory HSV lesions in immunocompromised adults, with drug interactions creating an important role for pharmacists.